tirzepatide in ozempic adults with obesity but not diabetes, leads to significantly greater weight loss than semaglutide over 72 weeks, and nearly double the patients on tirzepatide meet the 25% weight-loss target. http://ms.spr.ly/6183SkuIL Ozempic® (semaglutide) and Mounjaro™ (tirzepatide),

This extended observation period represents strong evidence of epitalon's favorable safety profile and relative absence of notable side effects over time

Florida has already obtained federal approval to import cheaper Canadian drugs

The preservative allows multiple entries into the vial over time while maintaining sterility, provided proper aseptic technique is followed during each withdrawal

Regular movement supports metabolic regulation and overall well being

Sanjeev Sockalingam of Obesity Canada says obesity is a serious medical condition and Wegovy is an important treatment option

Se realiz un seguimiento de los participantes durante una media de tres aos y medio, y los resultados fueron tan significativos que el ensayo, que deba durar hasta cinco aos, finaliz antes de tiempo